Annual revenue:
$54.07B+$8.26B(+18.03%)Summary
- As of today (April 17, 2025), AZN annual revenue is $54.07 billion, with the most recent change of +$8.26 billion (+18.03%) on December 31, 2024.
- During the last 3 years, AZN annual revenue has risen by +$16.66 billion (+44.51%).
- AZN annual revenue is now at all-time high.
Performance
AZN Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly revenue:
$14.89B+$1.33B(+9.78%)Summary
- As of today (April 17, 2025), AZN quarterly revenue is $14.89 billion, with the most recent change of +$1.33 billion (+9.78%) on December 31, 2024.
- Over the past year, AZN quarterly revenue has increased by +$2.21 billion (+17.45%).
- AZN quarterly revenue is now at all-time high.
Performance
AZN Quarterly revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM revenue:
$54.07B+$2.87B(+5.60%)Summary
- As of today (April 17, 2025), AZN TTM revenue is $54.07 billion, with the most recent change of +$2.87 billion (+5.60%) on December 31, 2024.
- Over the past year, AZN TTM revenue has increased by +$6.46 billion (+13.57%).
- AZN TTM revenue is now at all-time high.
Performance
AZN TTM revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
AZN Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +18.0% | +17.4% | +13.6% |
| 3 y3 years | +44.5% | +38.3% | +22.8% |
| 5 y5 years | +121.8% | +38.3% | +22.8% |
AZN Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +44.5% | at high | +38.3% | at high | +30.3% |
| 5 y | 5-year | at high | +121.8% | at high | +137.3% | at high | +114.2% |
| alltime | all time | at high | +796.0% | at high | +871.0% | at high | +2992.5% |
AstraZeneca Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $54.07B(+18.0%) | $14.89B(+9.8%) | $54.07B(+5.6%) |
| Sep 2024 | - | $13.56B(+4.8%) | $51.21B(+4.2%) |
| Jun 2024 | - | $12.94B(+2.0%) | $49.13B(+3.2%) |
| Mar 2024 | - | $12.68B(+5.4%) | $47.61B(+3.9%) |
| Dec 2023 | $45.81B(+3.3%) | $12.02B(+4.6%) | $45.81B(+1.8%) |
| Sep 2023 | - | $11.49B(+0.7%) | $44.99B(+1.1%) |
| Jun 2023 | - | $11.42B(+4.9%) | $44.48B(+1.5%) |
| Mar 2023 | - | $10.88B(-2.9%) | $43.84B(-1.2%) |
| Dec 2022 | $44.35B(+18.5%) | $11.21B(+2.0%) | $44.35B(-1.8%) |
| Sep 2022 | - | $10.98B(+2.0%) | $45.15B(+2.5%) |
| Jun 2022 | - | $10.77B(-5.4%) | $44.04B(+6.1%) |
| Mar 2022 | - | $11.39B(-5.2%) | $41.49B(+10.9%) |
| Dec 2021 | $37.42B(+40.6%) | $12.01B(+21.7%) | $37.42B(+14.0%) |
| Sep 2021 | - | $9.87B(+20.0%) | $32.82B(+11.1%) |
| Jun 2021 | - | $8.22B(+12.3%) | $29.53B(+7.1%) |
| Mar 2021 | - | $7.32B(-1.2%) | $27.58B(+3.6%) |
| Dec 2020 | $26.62B(+9.2%) | $7.41B(+12.6%) | $26.62B(+2.9%) |
| Sep 2020 | - | $6.58B(+4.8%) | $25.87B(+0.7%) |
| Jun 2020 | - | $6.28B(-1.2%) | $25.70B(+1.8%) |
| Mar 2020 | - | $6.35B(-4.7%) | $25.25B(+3.5%) |
| Dec 2019 | $24.38B(+10.4%) | $6.66B(+4.0%) | $24.38B(+1.0%) |
| Sep 2019 | - | $6.41B(+10.0%) | $24.14B(+4.6%) |
| Jun 2019 | - | $5.82B(+6.0%) | $23.07B(+3.0%) |
| Mar 2019 | - | $5.49B(-14.4%) | $22.40B(+1.4%) |
| Dec 2018 | $22.09B(-1.7%) | $6.42B(+20.2%) | $22.09B(+3.0%) |
| Sep 2018 | - | $5.34B(+3.6%) | $21.45B(-4.0%) |
| Jun 2018 | - | $5.16B(-0.4%) | $22.34B(+0.5%) |
| Mar 2018 | - | $5.18B(-10.4%) | $22.24B(-1.0%) |
| Dec 2017 | $22.46B(-2.3%) | $5.78B(-7.3%) | $22.46B(+0.9%) |
| Sep 2017 | - | $6.23B(+23.4%) | $22.27B(+2.5%) |
| Jun 2017 | - | $5.05B(-6.5%) | $21.74B(-2.5%) |
| Mar 2017 | - | $5.41B(-3.2%) | $22.29B(-3.1%) |
| Dec 2016 | $23.00B(-6.9%) | $5.58B(-2.0%) | $23.00B(-3.4%) |
| Sep 2016 | - | $5.70B(+1.7%) | $23.82B(-1.0%) |
| Jun 2016 | - | $5.60B(-8.4%) | $24.06B(-2.8%) |
| Mar 2016 | - | $6.12B(-4.4%) | $24.77B(+0.2%) |
| Dec 2015 | $24.71B(-6.9%) | $6.40B(+7.6%) | $24.71B(-1.3%) |
| Sep 2015 | - | $5.95B(-5.7%) | $25.02B(-2.6%) |
| Jun 2015 | - | $6.31B(+4.1%) | $25.69B(-1.7%) |
| Mar 2015 | - | $6.06B(-9.8%) | $26.14B(-1.5%) |
| Dec 2014 | $26.55B(+2.9%) | $6.72B(+1.6%) | $26.55B(-0.8%) |
| Sep 2014 | - | $6.61B(-2.3%) | $26.77B(+1.4%) |
| Jun 2014 | - | $6.76B(+4.7%) | $26.41B(+2.0%) |
| Mar 2014 | - | $6.46B(-6.9%) | $25.88B(+0.3%) |
| Dec 2013 | $25.81B(-7.7%) | $6.94B(+11.0%) | $25.81B(-1.3%) |
| Sep 2013 | - | $6.25B(+0.3%) | $26.15B(-1.6%) |
| Jun 2013 | - | $6.23B(-2.4%) | $26.58B(-1.6%) |
| Mar 2013 | - | $6.38B(-12.3%) | $27.01B(-3.4%) |
| Dec 2012 | $27.97B(-16.7%) | $7.28B(+9.0%) | $27.97B(-4.7%) |
| Sep 2012 | - | $6.68B(+0.3%) | $29.35B(-5.0%) |
| Jun 2012 | - | $6.66B(-9.4%) | $30.88B(-5.4%) |
| Mar 2012 | - | $7.35B(-15.1%) | $32.65B(-2.8%) |
| Dec 2011 | $33.59B(+1.0%) | $8.66B(+5.4%) | $33.59B(+0.1%) |
| Sep 2011 | - | $8.21B(-2.6%) | $33.55B(+0.9%) |
| Jun 2011 | - | $8.43B(+1.7%) | $33.24B(+0.8%) |
| Mar 2011 | - | $8.29B(-3.8%) | $32.98B(-0.9%) |
| Dec 2010 | $33.27B(+1.4%) | $8.62B(+9.1%) | $33.27B(-1.0%) |
| Sep 2010 | - | $7.90B(-3.4%) | $33.60B(-0.9%) |
| Jun 2010 | - | $8.18B(-4.6%) | $33.90B(+0.7%) |
| Mar 2010 | - | $8.58B(-4.1%) | $33.68B(+2.7%) |
| Dec 2009 | $32.80B(+3.8%) | $8.95B(+9.1%) | $32.80B(+2.3%) |
| Sep 2009 | - | $8.20B(+3.0%) | $32.05B(+1.3%) |
| Jun 2009 | - | $7.96B(+3.3%) | $31.63B(+0.0%) |
| Mar 2009 | - | $7.70B(-6.0%) | $31.63B(+0.1%) |
| Dec 2008 | $31.60B | $8.19B(+5.4%) | $31.60B(+0.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2008 | - | $7.78B(-2.3%) | $31.58B(+2.0%) |
| Jun 2008 | - | $7.96B(+3.6%) | $30.95B(+2.3%) |
| Mar 2008 | - | $7.68B(-6.0%) | $30.27B(+2.4%) |
| Dec 2007 | $29.56B(+11.6%) | $8.17B(+14.3%) | $29.56B(+3.6%) |
| Sep 2007 | - | $7.15B(-1.7%) | $28.54B(+2.3%) |
| Jun 2007 | - | $7.27B(+4.4%) | $27.91B(+2.4%) |
| Mar 2007 | - | $6.97B(-2.6%) | $27.26B(+3.0%) |
| Dec 2006 | $26.48B(+10.5%) | $7.15B(+9.8%) | $26.48B(+3.4%) |
| Sep 2006 | - | $6.52B(-1.6%) | $25.61B(+2.9%) |
| Jun 2006 | - | $6.63B(+7.2%) | $24.88B(+2.0%) |
| Mar 2006 | - | $6.18B(-1.7%) | $24.39B(+1.8%) |
| Dec 2005 | $23.95B(+11.8%) | $6.29B(+8.6%) | $23.95B(+2.1%) |
| Sep 2005 | - | $5.79B(-5.6%) | $23.46B(+2.3%) |
| Jun 2005 | - | $6.13B(+6.8%) | $22.94B(+3.8%) |
| Mar 2005 | - | $5.74B(-1.0%) | $22.09B(+3.1%) |
| Dec 2004 | $21.43B(+13.7%) | $5.80B(+10.1%) | $21.43B(+4.5%) |
| Sep 2004 | - | $5.26B(-0.4%) | $20.50B(+2.4%) |
| Jun 2004 | - | $5.29B(+4.2%) | $20.01B(+4.3%) |
| Mar 2004 | - | $5.07B(+4.1%) | $19.18B(+1.8%) |
| Dec 2003 | $18.85B(+5.6%) | $4.88B(+2.0%) | $18.85B(+0.8%) |
| Sep 2003 | - | $4.78B(+7.3%) | $18.69B(+1.7%) |
| Jun 2003 | - | $4.45B(-6.1%) | $18.38B(+0.8%) |
| Mar 2003 | - | $4.74B(+0.5%) | $18.24B(+2.2%) |
| Dec 2002 | $17.84B(+8.3%) | $4.72B(+5.6%) | $17.84B(+1.6%) |
| Sep 2002 | - | $4.47B(+3.6%) | $17.56B(+3.0%) |
| Jun 2002 | - | $4.31B(-0.8%) | $17.05B(+1.3%) |
| Mar 2002 | - | $4.35B(-2.1%) | $16.84B(+2.2%) |
| Dec 2001 | $16.48B(-9.0%) | $4.44B(+12.4%) | $16.47B(-11.0%) |
| Sep 2001 | - | $3.95B(-3.6%) | $18.50B(+1.0%) |
| Jun 2001 | - | $4.10B(+3.0%) | $18.33B(+0.7%) |
| Mar 2001 | - | $3.98B(-38.6%) | $18.21B(+0.5%) |
| Dec 2000 | $18.12B(+19.7%) | $6.48B(+71.6%) | $18.12B(+34.7%) |
| Sep 2000 | - | $3.77B(-5.1%) | $13.45B(-3.6%) |
| Jun 2000 | - | $3.98B(+2.3%) | $13.96B(-3.8%) |
| Mar 2000 | - | $3.89B(+114.5%) | $14.50B(-4.2%) |
| Dec 1999 | $15.13B(+33.7%) | $1.81B(-57.7%) | $15.13B(-12.9%) |
| Sep 1999 | - | $4.28B(-5.4%) | $17.38B(+12.6%) |
| Jun 1999 | - | $4.52B(0.0%) | $15.43B(+9.4%) |
| Mar 1999 | - | $4.52B(+11.4%) | $14.10B(+17.5%) |
| Dec 1998 | $11.32B(+31.8%) | $4.06B(+74.2%) | $12.00B(+17.3%) |
| Sep 1998 | - | $2.33B(-27.0%) | $10.23B(+2.3%) |
| Jun 1998 | - | $3.19B(+32.0%) | $10.00B(+10.0%) |
| Mar 1998 | - | $2.42B(+5.7%) | $9.09B(+1.5%) |
| Dec 1997 | $8.59B(-6.5%) | $2.29B(+9.0%) | $8.96B(-20.2%) |
| Sep 1997 | - | $2.10B(-8.1%) | $11.22B(-1.9%) |
| Jun 1997 | - | $2.28B(0.0%) | $11.44B(+0.0%) |
| Mar 1997 | - | $2.28B(-49.9%) | $11.43B(+0.0%) |
| Dec 1996 | $9.18B(+21.3%) | $4.56B(+97.0%) | $11.43B(+32.4%) |
| Sep 1996 | - | $2.31B(+1.5%) | $8.63B(+4.6%) |
| Jun 1996 | - | $2.28B(0.0%) | $8.26B(+3.3%) |
| Mar 1996 | - | $2.28B(+29.2%) | $7.99B(+3.4%) |
| Dec 1995 | $7.57B(+8.1%) | $1.76B(-8.9%) | $7.73B(-0.8%) |
| Sep 1995 | - | $1.94B(-4.1%) | $7.80B(+2.4%) |
| Jun 1995 | - | $2.02B(-0.0%) | $7.61B(+2.4%) |
| Mar 1995 | - | $2.02B(+10.4%) | $7.43B(+2.5%) |
| Dec 1994 | $7.00B(+6.6%) | $1.83B(+4.2%) | $7.25B(+4.2%) |
| Sep 1994 | - | $1.75B(-4.6%) | $6.96B(+3.2%) |
| Jun 1994 | - | $1.84B(0.0%) | $6.74B(+1.3%) |
| Mar 1994 | - | $1.84B(+19.8%) | $6.66B(+1.3%) |
| Dec 1993 | $6.57B(+8.8%) | $1.53B(-0.2%) | $6.57B(+30.5%) |
| Sep 1993 | - | $1.54B(-12.1%) | $5.03B(+44.0%) |
| Jun 1993 | - | $1.75B(0.0%) | $3.50B(+100.0%) |
| Mar 1993 | - | $1.75B | $1.75B |
| Dec 1992 | $6.03B(-17.9%) | - | - |
| Dec 1991 | $7.35B(+0.0%) | - | - |
| Dec 1990 | $7.35B | - | - |
FAQ
- What is AstraZeneca annual revenue?
- What is the all time high annual revenue for AstraZeneca?
- What is AstraZeneca annual revenue year-on-year change?
- What is AstraZeneca quarterly revenue?
- What is the all time high quarterly revenue for AstraZeneca?
- What is AstraZeneca quarterly revenue year-on-year change?
- What is AstraZeneca TTM revenue?
- What is the all time high TTM revenue for AstraZeneca?
- What is AstraZeneca TTM revenue year-on-year change?
What is AstraZeneca annual revenue?
The current annual revenue of AZN is $54.07B
What is the all time high annual revenue for AstraZeneca?
AstraZeneca all-time high annual revenue is $54.07B
What is AstraZeneca annual revenue year-on-year change?
Over the past year, AZN annual revenue has changed by +$8.26B (+18.03%)
What is AstraZeneca quarterly revenue?
The current quarterly revenue of AZN is $14.89B
What is the all time high quarterly revenue for AstraZeneca?
AstraZeneca all-time high quarterly revenue is $14.89B
What is AstraZeneca quarterly revenue year-on-year change?
Over the past year, AZN quarterly revenue has changed by +$2.21B (+17.45%)
What is AstraZeneca TTM revenue?
The current TTM revenue of AZN is $54.07B
What is the all time high TTM revenue for AstraZeneca?
AstraZeneca all-time high TTM revenue is $54.07B
What is AstraZeneca TTM revenue year-on-year change?
Over the past year, AZN TTM revenue has changed by +$6.46B (+13.57%)